Briumvi, TG Therapeutics' multiple sclerosis drug, achieved $182.7 million in US net product revenues in Q4 2025, marking a 19.5% sequential growth. The company projects global revenues between $875 million and $900 million for 2026. Key upcoming catalysts include the ENHANCE trial results expected mid-2026 and pivotal subcutaneous Briumvi data anticipated by late 2026 or early 2027, both of which could significantly boost the drug's market potential. Additionally, TG Therapeutics has a $300 million buyback program that may support the stock price, though risks remain from potential negative updates.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
B&M European Value Retail's first-quarter update has divided analysts, with Deutsche Bank upgrading the stock to 'hold' citing stabilizing profit margins and a sensible turnaround strategy by new CEO Tjeerd Jegen. Deutsche Bank raised its profit fore...
Telo Genomics announced positive interim results from a clinical study analyzing blood samples of multiple myeloma patients to predict relapse risk using 3D telomere analysis. The test showed strong predictive accuracy, potentially offering a less in...
Meta now notifies parents if their teen talks about suicide or self-harm with its AI chatbot and is developing a feature to contact emergency services if risk is detected. This move addresses concerns about AI chatbots handling crisis conversations, ...
NTG Clarity Networks announced new purchase orders and contract renewals totaling about CAD 16.6 million, reflecting strong demand for its software development and digital transformation services. This includes $2.3 million from a real estate client ...
